StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s): SZLSF

Healthcare Biotechnology

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.

TSX:SZLS - Post by User

StageZero Life Sciences Ltd > Aristotle testing volumes and daily schedule

<< Previous

Bullboard Posts

Next >>

Comment by LithLoveron Jan 23, 2022 8:01pm

166 Views

Post# 34350638

RE:Aristotle testing volumes and daily schedule

And just like that the 2 wednesday Jan 26 appointments for next week are gone.

LithLover wrote: If you check the scheduled call link below, there are usually on average 15 appointments per day 6 days a week.

https://careoncology.com/reserve-a-call-with-a-case-manager/

For the last month these appointments have all been taken. For example if you look at the schedule there are none available this Monday or Tuesday and only 2 left on Wednesday (and yes the appointments were there last week when I checked). This has been happening for weeks now since the GTA roll out. The company recently hired 2 case managers to handle the volume. The postings are down so I assume they were hired.

Now even if 2/3 or 10 of the 15 sign up for tests thats 60 tests a week (6 days) about 250 tests a month. Revenue is $2,000 CAD or $1500 USD per test. Could even be multiple tests if families or couples are calling in together. But stick with 10 tests per day. $20,000 a day or $500,000 a month. $1.5 million a quarter. $6 million a year and thats just Aristotle based on a single test not families or multiple tests. There is also AVRT which was doing $4 million a year and growing prior to the acquisition. Add in Covid revenue, other cancer tests and more follow up revenue from the Care protocals and revenues could be over $10 million annually. On the CEO video interview andin the job description for Legal Counsel both hinting at the Care UK roll out. More revnues will be coming from there as well.

At 10-14 times annual revenue that values the company between $100-140 million which is $1.25-1.75 a share. Even at half that revenue the share price should be $0.60-0.85. Way undervalued at this level and still being manipulated.

Not a matter of if it goes back over $1 but when.

24

25

26

2

27

10

28

10

29

3